Biotech Stocks
3 Undervalued Biotech Stocks With Upcoming Catalysts
New drug approvals and the rollout of just-commercialized products will be the catalysts that send these undervalued stocks rallying. Negative sentiment has dropped their prices so low that any rally from these prices could return investors explosive gains. Despite four straight weeks of gains in the S&P 500, the biotech sector continues to be mired […]
3 Post-Selloff Bargains To Buy In Biotech
The biotech sector is offering valuations so cheap right now that in some cases you can buy shares in a company for less than the cash they have in the bank. Sentiment won’t stay this low forever, and when it turns these three stocks will rally back to their former highs. It has been an […]
Buy These 4 Undervalued Biotech Stocks On Sale Today
Valuations this cheap haven’t been available in biotech since 2011, and buying any of these four stocks right now could be one of your best investing decisions of 2016. Don’t miss out on the chance to buy these undervalued biotechs that already have commercialized products for what is almost a 50% discount. It has been […]
3 Small Cap Biotechs Ripe For A Takeover
Big biotech is about to go on a shopping spree to replenish their pipelines as many small cap biotechs are selling for lows not seen since 2011. Here are three likely candidates that might get snatched up soon for big premiums. Few sectors of the stock market have been hit harder in 2016 than the […]
Be Smarter Than the Smartest Investors
A couple times a year the biotech sector gives the retail investor the chance to look smarter than the “smart money” investor. That is, the retail investor can pick up shares of a promising biotech company at a better price than what the institutional investor paid. The institutional investor spent a lot of time and […]
4 Undervalued Bargains To Buy In Biotech
Editor’s Note: This article discusses opportunities in the biotech space, which is often populated with small and micro cap stocks. Sporting their cheapest valuations since 2011 and superior long-term values over the rest of the market, now is the time to shop the bargain bin in biotech. See Bret Jensen’s top four picks to start […]
Tiny Biotech Stock Set To Go Higher With Cure For Something Other Than Cancer
Traditionally, biotech investors are handsomely rewarded for owning shares of companies working on treatments for cancer, once approved by the FDA. Yet there is one company poised to skyrocket on a drug that cures a non-cancerous ailment. Sophiris Bio ($SPHS, $1.67) is knocking on the door of an effective treatment for enlarged prostate. Located in […]
Investing In Biotech For Yield
If the announcement by the Federal Reserve to raise interest rates was not enough to get your heart racing again about collecting guaranteed income from a CD, consider investing in a biotech stock that generates income… and lots of it. Most investors look to biotech stocks for speculative and spectacular gains even if they are […]
Biotech Penny Stocks To Soar In 2014!
The biotech sector delivered huge gains for investors in 2013. Yes, the Nasdaq Composite’s 40% increase last year was impressive. But the 65% gain in the Nasdaq Biotechnology Index was truly outstanding! No question about it, 2013 was a banner year for biotech stocks. And the good news is… the sector is poised to continue […]
Don’t Miss Out On The Huge Profits In Biotech Penny Stocks!
Biotechnology is one industry that is saturated with penny-sized companies. It’s the nature of the industry. A new technology or a breakthrough in medical research can yield a new drug worth billions of dollars. It’s a siren’s song that attracts many top medical researchers, scientists, and of course private equity investors to the field. And […]
Biotech Penny Stocks… Love Them Or Hate Them?
Few areas of the market are as polarizing as biotech penny stocks. Some investors love these super volatile stocks and trade them regularly. Others hate them with a passion and won’t touch them with a ten foot pole. But whether you love them or hate them, you have to admit they offer huge profit potential. […]
